These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37815782)

  • 1. Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial.
    Kim EH; Bird JA; Keet CA; Virkud YV; Herlihy L; Ye P; Smeekens JM; Guo R; Yue X; Penumarti A; Qaqish B; Li Q; Kulis MD; Burks AW
    J Allergy Clin Immunol; 2024 Jan; 153(1):173-181.e10. PubMed ID: 37815782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.
    Kim EH; Keet CA; Virkud YV; Chin S; Ye P; Penumarti A; Smeekens J; Guo R; Yue X; Li Q; Kosorok MR; Kulis MD; Burks AW
    J Allergy Clin Immunol; 2023 Jun; 151(6):1558-1565.e6. PubMed ID: 36828080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
    Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW;
    Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.
    Kim EH; Yang L; Ye P; Guo R; Li Q; Kulis MD; Burks AW
    J Allergy Clin Immunol; 2019 Nov; 144(5):1320-1326.e1. PubMed ID: 31493887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.
    Narisety SD; Frischmeyer-Guerrerio PA; Keet CA; Gorelik M; Schroeder J; Hamilton RG; Wood RA
    J Allergy Clin Immunol; 2015 May; 135(5):1275-82.e1-6. PubMed ID: 25528358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy.
    Burk CM; Kulis M; Leung N; Kim EH; Burks AW; Vickery BP
    Clin Exp Allergy; 2016 Feb; 46(2):347-53. PubMed ID: 26362760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
    Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
    Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.
    Burks AW; Wood RA; Jones SM; Sicherer SH; Fleischer DM; Scurlock AM; Vickery BP; Liu AH; Henning AK; Lindblad R; Dawson P; Plaut M; Sampson HA;
    J Allergy Clin Immunol; 2015 May; 135(5):1240-8.e1-3. PubMed ID: 25656999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
    Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
    Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial.
    Fleischer DM; Burks AW; Vickery BP; Scurlock AM; Wood RA; Jones SM; Sicherer SH; Liu AH; Stablein D; Henning AK; Mayer L; Lindblad R; Plaut M; Sampson HA;
    J Allergy Clin Immunol; 2013 Jan; 131(1):119-27.e1-7. PubMed ID: 23265698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.
    Bird JA; Spergel JM; Jones SM; Rachid R; Assa'ad AH; Wang J; Leonard SA; Laubach SS; Kim EH; Vickery BP; Davis BP; Heimall J; Cianferoni A; MacGinnitie AJ; Crestani E; Burks AW;
    J Allergy Clin Immunol Pract; 2018; 6(2):476-485.e3. PubMed ID: 29092786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization.
    Kim EH; Bird JA; Kulis M; Laubach S; Pons L; Shreffler W; Steele P; Kamilaris J; Vickery B; Burks AW
    J Allergy Clin Immunol; 2011 Mar; 127(3):640-6.e1. PubMed ID: 21281959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
    O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
    Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
    Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M
    Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
    Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
    J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
    Fernandez-Rivas M; Vereda A; Vickery BP; Sharma V; Nilsson C; Muraro A; Hourihane JO; DunnGalvin A; du Toit G; Blumchen K; Beyer K; Smith A; Ryan R; Adelman DC; Jones SM
    Allergy; 2022 Mar; 77(3):991-1003. PubMed ID: 34320250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Food-specific sublingual immunotherapy is well tolerated and safe in healthy dogs: a blind, randomized, placebo-controlled study.
    Maina E; Pelst M; Hesta M; Cox E
    BMC Vet Res; 2017 Jan; 13(1):25. PubMed ID: 28100257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximum Dose Food Challenges Reveal Transient Sustained Unresponsiveness in Peanut Oral Immunotherapy (POIMD Study).
    Davis CM; Anagnostou A; Devaraj S; Vita DT; Rivera F; Pitts K; Hearrell M; Minard C; Guffey D; Gupta M; Watkin L; Orange JS; Anvari S
    J Allergy Clin Immunol Pract; 2022 Feb; 10(2):566-576.e6. PubMed ID: 34890827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial.
    Fleischer DM; Greenhawt M; Sussman G; Bégin P; Nowak-Wegrzyn A; Petroni D; Beyer K; Brown-Whitehorn T; Hebert J; Hourihane JO; Campbell DE; Leonard S; Chinthrajah RS; Pongracic JA; Jones SM; Lange L; Chong H; Green TD; Wood R; Cheema A; Prescott SL; Smith P; Yang W; Chan ES; Byrne A; Assa'ad A; Bird JA; Kim EH; Schneider L; Davis CM; Lanser BJ; Lambert R; Shreffler W
    JAMA; 2019 Mar; 321(10):946-955. PubMed ID: 30794314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peanut-Specific IgG4 and IgA in Saliva Are Modulated by Peanut Oral Immunotherapy.
    Smeekens JM; Baloh C; Lim N; Larson D; Qin T; Wheatley L; Kim EH; Jones SM; Burks AW; Kulis MD
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3270-3275. PubMed ID: 35944894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.